Clinical Trial

Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This first-in-human (FIH) study aims to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JANX011 dosed subcutaneously (and potentially intravenously) in healthy adult volunteers (HVs) to gain insight into its therapeutic utility in patients with autoimmune diseases.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-05.
Status change: Not Yet Recruiting → Recruiting 2026-04-20
Trial Details
NCT Number NCT07291323
Lead Sponsor Janux Therapeutics
Conditions Autoimmune
Enrollment 60 participants
Start Date 2026-02-16
Primary Completion 2026-10 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-23